Virtual reality, meet virtual clinical trials.
AppliedVR will test its virtual-reality-based digital therapeutics across five studies using the decentralized clinical trials software from Curebase, the companies said Thursday.
The life sciences industry has immersed itself in decentralized, or virtual, trials since the onset of the COVID-19 pandemic, and, now, AppliedVR wants to further test its 3D, immersive headset and goggles in patients’ homes.
The Los Angeles medical technology company got the FDA breakthrough designation for its platform’s use in chronic lower back pain and treatment-resistant fibromyalgia last October. AppliedVR works with more than 240 hospitals to provide the VR therapy for acute pain after surgery or during hospitalization.
The two startups are linking arms after each having raised series A rounds earlier this year. AppliedVR snagged $29 million in March, and Curebase picked up $15 million in May.
Curebase will help AppliedVR test the platform across the digital therapeutics company’s entire pipeline, which also includes earlier-stage trials as a replacement for opioid prescriptions, treatment for generalized anxiety and other undisclosed indications, said Curebase CEO Tom Lemberg in an interview with Fierce Biotech.
Read the source article at fiercebiotech.com